3-D DNA methylation phenotypes correlate with cytotoxicity levels in prostate and liver cancer cell models by unknown
Gertych et al. BMC Pharmacology and Toxicology 2013, 14:11
http://www.biomedcentral.com/2050-6511/14/11RESEARCH ARTICLE Open Access3-D DNA methylation phenotypes correlate with
cytotoxicity levels in prostate and liver cancer
cell models
Arkadiusz Gertych1,3, Jin Ho Oh1,2, Kolja A Wawrowsky1,4, Daniel J Weisenberger5 and Jian Tajbakhsh1,2*Abstract
Background: The spatial organization of the genome is being evaluated as a novel indicator of toxicity in
conjunction with drug-induced global DNA hypomethylation and concurrent chromatin reorganization. 3D
quantitative DNA methylation imaging (3D-qDMI) was applied as a cell-by-cell high-throughput approach to
investigate this matter by assessing genome topology through represented immunofluorescent nuclear distribution
patterns of 5-methylcytosine (MeC) and global DNA (4,6-diamidino-2-phenylindole = DAPI) in labeled nuclei.
Methods: Differential progression of global DNA hypomethylation was studied by comparatively dosing zebularine
(ZEB) and 5-azacytidine (AZA). Treated and untreated (control) human prostate and liver cancer cells were subjected
to confocal scanning microscopy and dedicated 3D image analysis for the following features: differential nuclear
MeC/DAPI load and codistribution patterns, cell similarity based on these patterns, and corresponding differences in
the topology of low-intensity MeC (LIM) and low in intensity DAPI (LID) sites.
Results: Both agents generated a high fraction of similar MeC phenotypes across applied concentrations. ZEB
exerted similar effects at 10–100-fold higher drug concentrations than its AZA analogue: concentration-dependent
progression of global cytosine demethylation, validated by measuring differential MeC levels in repeat sequences
using MethyLight, and the concurrent increase in nuclear LIM densities correlated with cellular growth reduction
and cytotoxicity.
Conclusions: 3D-qDMI demonstrated the capability of quantitating dose-dependent drug-induced spatial
progression of DNA demethylation in cell nuclei, independent from interphase cell-cycle stages and in conjunction
with cytotoxicity. The results support the notion of DNA methylation topology being considered as a potential
indicator of causal impacts on chromatin distribution with a conceivable application in epigenetic drug toxicology.
Keywords: DNA methylation phenotype, Chromatin distribution, High-throughput cell assay, 3D image analysis,
MethyLight, Repetitive element, Epigenetic drugBackground
DNA methylation is a crucial epigenetic modification of the
human genome beyond the DNA sequence level that is
involved in regulating many cellular processes [1]. Cancer
cells frequently exhibit abnormally high levels of DNA
methylation in gene-specific CpG-rich promoter regions
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reproduction in any medium, provided the ornon-CpG islands within the major part of the genome
known as heterochromatin [6,7], which plays a key
role in nuclear architecture and genome stability [8-10]. It
is now clear that DNA hypomethylation in human cancer
is also very frequent and affects more cytosine residues
than does DNA hypermethylation, accounting for a net
loss of 5-methylcytosine (global DNA hypomethylation),
as observed in many cancers [11-14]. The reversible
nature of epigenetic imbalances in various types of cancers
constitutes an attractive therapeutic target. The goal of
epigenetic therapy in cancer is the reprogramming of
aberrant cells towards normal phenotypes. In this regard,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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on screening the effect of candidate agents on the levels of
molecular cell signaling and metabolism. However, in
recent years of the post-genomic era, chromatin conform-
ation and the higher–order genome organization, which
set the framework for the global orchestration as well the
locus-specific regulation of gene expression in the human
cell nucleus [15-18], are gaining more attention in therapy;
the reason being that these functional structures can
become affected as a consequence of epigenetic interfer-
ence by chromatin-modifying agents such as inhibitors of
DNA methylation [19].
Catalytic DNA methyltransferase (DNMT) inhibitors
have been so far categorized into two classes: nucleoside
analogues and non-nucleoside analogues [20]. The two
nucleoside analogues, 5-azacytidine (AZA, Vidaza™) and
5-aza-20-deoxycytidine (decitabine, Dacogen™) are the most
advanced in their category, having received US Federal
Drug Agency (FDA) approval for their use in treating
myelodysplastic syndrome (MDS) and hematopoietic ma-
lignancies [21,22]. Zebularine (ZEB) or 1-β-D-ribofura-
nosyl-2(1H)-pyrimidone has recently emerged as a new
DNMT inhibitor (DNMTi), with properties that makes it a
potential drug candidate for oral administration: (i) stability
at pH ranges between 1.0 and 7.0 in aqueous solutions, (ii)
far less toxicity than AZA and decitabine to cultured cells,
and (iii) no detectable toxicity in a T-cell lymphoma mouse
model [23-27].
The specific mechanism of DNA methylation
alterations induced by azacytidine nucleoside analogues
is complex and not fully understood. Azacytidine is
thought to form a stable covalent bond with DNMTs
after its incorporation into genomic DNA, thereby trap-
ping the enzyme and sequestering it from transferring
methyl groups to other regions of the genome [28-30].
Such a passive mechanism of DNA demethylation as a
result of exposure to DNMTi has been proposed and is
thought to progress with several cell divisions, after
which DNMT levels increase and specific gene regions
show re-methylation. Azacytidine treatment of cells also
was shown to induce degradation of DNMT1 via the
ubiquitin-activating proteosomal pathway [31], as well as
p53-mediated cell cycle arrest and DNA repair [32].
Chromatin packaging and organization are altered in cells
treated with azacytidine. Nucleosome depletion of sym-
metrically demethylated gene loci have been demonstrated
after drug treatment [33]. However, it should be noted
that there are additional reports indicating that genomic
regions with AZA DNA-DNMT adducts are improperly
packaged and transcriptional activation can only occur
with DNA repair and recruitment of other protein
factors [34,35].
To date, differential DNA methylation analysis has
been quantitatively performed mostly by means ofmolecular approaches including electrophoretic, chroma-
tographic, PCR-based, array-based, and sequencing tech-
nologies [36,37]. Furthermore, evidences indicate that
DNMTi also influence repressive histone marks leading to
changes in nucleosome positioning [33,34]. Hence, a novel
nucleosome footprinting assay was developed, which takes
advantage of improvements in these technologies and
focuses on the characterization of locus-specific as well as
genome-wide chromatin conformation with respect to
DNA methylation on a single molecule level [38,39]. Such
an analytical tool can be used to characterize the differen-
tial chromatin states and changes thereof that can occur
under drug influence and would benefit therapeutic
design: as demethylating drugs may, in addition to their
physiologic role, also affect chromatin architecture and
related gene expression programs in cells [40-47]. The
structure and function of the human genome are so intri-
cately intertwined that understanding its regulation
requires viewing the genome as a dynamic three-
dimensional entity that emerges from iterations of
dynamic folding of the primary chromatin structure, the
so-called nucleosomal array: also considering the mass of
heterochromatin that is largely repressed and condensed
through DNA methylation and histone-tail modifications,
which are perturbed in complex diseases [17,18]. The im-
munodeficiency, centromere instability and facial anomal-
ies (ICF) syndrome is a classic example, in which normally
highly compacted juxtacentromeric satellite DNA is found
hypomethylated and decondensed in chromosomes 1 and
16 [48]. Therefore, the higher genome organization of
DNA provides an additional layer of cell-specific informa-
tion that could render itself valuable in the evaluation of
drug action, as it has potential to be translated into high-
throughput and cost-efficient pre-clinical genotoxicity
assays [19]. In this sense, little is known about the spatial
progression of DNA hypomethylation in cell nuclei in re-
sponse to DNMTi. The analysis of global nuclear DNA
methylation patterns could provide a useful means in
assessing said epigenetic effect of this class and possibly
other classes of drugs in a large number of single cells, as
the underlying molecular processes may involve large-
scale chromatin reorganization visible by light microscopy
[40-44,49-51]. Recently introduced, 3D-qDMI, can meas-
ure DNA methylation changes in situ, through the differ-
ential analysis of relevant nuclear structures that are
represented by methylated CpG-dinucleotides (MeC) and
global DNA [40-42] (Figure 1). Our analyses revealed
significant differences in image patterns of MeC and
heterochromatin-derived signals between untreated AtT20
mouse pituitary tumor cells and a subpopulation of these
cells treated with AZA, which has been reported to change
DNA methylation patterns on a genomic scale [52].
Furthermore, the recently upgraded methodology was able
to monitor the dual effect of demethylating agents in
Figure 1 Workflow of 3D quantitative DNA methylation imaging and analysis. Image data acquired by high-resolution microscopy is
subjected to a pre-processing step, in which cell nuclei (as areas of interest) are segmented, followed by DNA methylation phenotyping. This step
comprises three modules, by which recorded signals in the MeC and DAPI channels are extracted for measuring: global MeC load, MeC/DAPI
signal codistribution, and MeC and DAPI signal topology within the nuclear space. The retrieved information is used to assess the capacity of a
drug for DNA demethylation and concurrent chromatin reorganization.
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and (b) the subsequent reorganization of highly compact
heterochromatic regions of the genome as reflected by a
significant decrease of DAPI intensity in the relevant
nuclear areas. The effects resulted in LIM and LID sites,
whose distributions can be mapped within cell nuclei [44].
This approach supports profiling at single-cell level, and
provides a rapid display of cell-specific DNA methylation
(MeC) phenotypes that is related to drug response in
targeted cells. Initial results obtained with 3D-qDMI
indicated towards the relatively gentle effect of zebularine
on the genome, an observation that is concordant with
reported studies based on molecular profiling. Initial
proof-of-principle analyses focusing more on technology
development were restricted to the application of one
concentration per epigenetic drug. Here we report on the
first-time probing of the 3D-qDMI system’s utility in a
dose-dependent manner: by administration of a larger con-
centration range of the relatively more gentle nucleoside
zebularine in comparison to its extensively characterized
more aggressive analogue 5-azacytidine [23-27,53,54]. The
notion was to follow a more gradual DNA demethylation
effect of the agents on 5-methylcytosine topology, along
with cytotoxicity evaluations, in the two in vitro models,
DU145 prostate cancer cells and Huh-7 hepatocarcinoma
cells, which have known sensitivity to both drugs [55-59].
Methods
Cell culture and drug treatment
DU145 human prostate cancer cells were obtained from
American Tissue Culture Collection (catalog number
HTB-81, ATCC). The vendor certifies authentication of
cells using a variety of techniques such as short tandem
repeat (STR) analysis and cytogenetic analyses (G-banding,
fluorescence in situ hybridization). Huh-7 cells were a gift
from Dr. Vaithilingaraja Arumugaswami (Cedars-Sinai
Medical Center, Los Angeles, CA). The cells were
propagated for less than six months after receipt and resus-
citation. Cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM, Cellgro) supplemented with 10%
newborn calf serum, and 1% antibiotic/antimycotic (1000
units/ml penicillin G sodium, 10 mg/ml streptomycinsulfate) (Gemini Bio-Products), in 5% CO2, 37°C. Cells
were plated at 1 × 105 cells onto coverslips in multi-well
plates in replicates, and allowed to attach for 24 hours. For
dose dependency assay, wells were divided into two groups:
(i) control populations that were not treated for 72 hours,
and (ii) populations of cells treated with two different drugs
at different concentrations for 72 hours: 0.5 μM, 1 μM,
2.5 μM, 5 μM, 10 μM and 20 μM of 5-azacytidine
(Sigma-Aldrich), and 8 μM, 40 μM, 200 μM, 500 μM
and 1000 μM of zebularine (Sigma-Aldrich), all in DMEM.
For all cells, drug concentrations were freshly prepared
prior to administration, and the drug-medium mixture was
changed every 24 hours. Subsequently, cells were partially
fixed for immunofluorescence and partially harvested for
cytotoxicity testing by flow cytometry.
Cell synchronization
DU145 prostate cancer cells were arrested in G0/G1 and
G2-phases following previously established protocols
[60,61]. Briefly, cells were seeded onto glass coverslips at a
concentration of 105 cells/ml for immunofluorescence
staining and subsequent imaging via confocal microscopy.
A parallel set of cultures (at the same concentration) was
maintained in culture flasks, for flow cytometry. All cells
were first allowed to attach and grow for 24 hours in regu-
lar proliferative medium (DMEM/10% FBS/1% penicillin/
1% streptomycin), which was then replaced by serum-
deprived DMEM for 72 hours, followed by a recovery
period of 4 hours, in which cells were maintained again in
regular proliferative medium. G0/G1 populations were par-
tially fixed at this point for use in either immunocytochem-
istry or FACS. The remainder cultures were processed for a
double-thymidine block to enrich cells in G2-phase: (i) first
blocking with deoxythymidine (Sigma) at 2 mM for
18 hours, (ii) recovery in regular proliferative medium
for 12 hours to escape S-phase, (iii) second blocking
with 2 mM deoxythymidine for another 18 hours, and
(iv) second recovery in regular proliferative medium
for 8 hours, to release cells into G2. At this point G2-cells
were fixed for further experimentation. Enrichment effi-
ciency was checked by propidium iodide (PI) staining of
cells and nuclear DNA content analysis, following standard
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cells were fixed in 70% ethanol/PBS and maintained
for at least 4 hours at 4°C; then incubated in 5 μg/ml
PI (Sigma) for 30 minutes at 37°C immediately prior
to flow cytometry with a FACScan (Becton Dickinson).
FACS data were analyzed using the ModFit LT program
(Verity Software House, Topsham, ME, USA).
Cytotoxicity assay
Induction of apoptosis and cell viability was analyzed in
cells that were treated as replicates in parallel to cells
that were subsequently analyzed by immunofluores-
cence. For that purpose, 2×105 cells/ml were stained
with Annexin V (7-AAD) and PI, respectively [63]. In
essence, trypsinated cells from parallel wells were
processed with the Annexin V-FITC Apoptosis Detec-
tion Kit I (BD Biosciences). Cells (1×105) were incubated
for 15 minutes at room temperature with 7-AAD and PI
in a total volume of 510 μl comprised of 5 μl of each of
the fluorescent dyes, each and 500 μl of 1X binding
buffer. Controls with unstained cells and cells stained
with either dye alone were used for FACS setup. Samples
were analyzed at emission wavelengths of 530 nm
(for Annexin V-FITC) and 650 nm (for PI) using
FACScan. The fluorescence of 104 cells was acquired and
analyzed with CellQuest software (Becton Dickinson).
Immunofluorescence and image acquisition
In order to preserve the three-dimensional structure,
cells cultured on glass coverslips in 12-well microplates
(Costar, Corning) were fixed with 4% paraformaldehyde/
phosphate buffered saline (PBS) (Sigma-Aldrich) and
processed for immunofluorescence as previously
described [64]. The following antibody sets were used: a
monoclonal mouse anti-5-MeC antibody (Clone 33D3,
Aviva Systems Biology, San Diego, CA) together with an
Alexa488-conjugated polyclonal donkey anti-mouse IgG
(H + L) (Invitrogen), and a polyclonal rabbit anti-
H3K9me3 antibody (Active Motif ) together with an
Alexa647-conjugated chicken anti-rabbit IgG (H + L)
(Invitrogen). All specimens were counterstained with
DAPI. Specimens were imaged by a confocal laser-
scanning microscope (TCS SP5 X Supercontinuum,
Leica Microsystems Inc.) that allows for any excitation
line within the continuous range of 470 to 670 nm, in
1 nm increments. The system was additionally equipped
with a 405 nm diode laser line for excitation of DAPI
fluorescence. Serial optical sections were collected at
increments of 200–300 nm with a Plan-Apo 63X 1.3
glycerol immersion lens (pinhole size was 1.0 Airy unit).
To avoid bleed-through, the imaging of each channel
was performed sequentially. The typical image size was
2048 × 2048, with a respective voxel size of 116 nm ×
116 nm × 230.5 nm (x, y, and z axes), and resolution was12 bits per pixel in all channels. Fluorescence intensity
of MeC-signals and DAPI-signals from optical two-
dimensional sections were recorded into separate 3D
channels. Raw images were obtained as Leica Image
Format (lif ) and offline-converted to a series of TIFFs
for downstream image analysis.
3D image analysis
Image analysis was performed in three main steps, as
comprehensively described in [43,44]: 1) image segmen-
tation resulting in the delineation of a 3D shell for each
individual nucleus; 2) extraction of MeC and DAPI
signal intensity distributions within each 3D shell; 3)
assessment of cell population heterogeneity through 2D
histograms of MeC versus DAPI distribution patterns, util-
izing K-L divergence, and 4) the mapping of LIMs and
LIDs within individual nuclei. A newly added analytical
component for this study was the calculation of mean
intensity of MeC signals. Images in each two-channel 3D
stack were acquired under nearly identical conditions and
modality settings, and so the drift of the settings during
acquisition is considered minimal and can be neglected.
For codistribution analysis, the MeC and DAPI signals
were mapped as respective 2D scatter plots, and following
[43] the Kullback–Leibler (KL) divergences were calculated
between individual 2D plots (nuclei) and the reference 2D
plot (cumulative plot from all nuclei in one drug/concen-
tration experiment). Based on the KL value, cells were
categorized as: similar KLG ∈ [0, 0.5), likely similar KLG ∈
[0.5, 2), unlikely similar KLG ∈ [2, 4.5), and dissimilar
KLG ∈ [4.5,∞) in order to evaluate a ratio of similar and
dissimilar cells. For localization of resulting LIM and LID
sites, the nuclei were analyzed by an algorithm introduced
in [44]. Briefly, segmented nuclei were eroded at a constant
voxel rate of 1.32 μm× 1.3 μm× 0.25 μm, and MeC and
DAPI signals were recorded as integrated intensity values
within each nuclear shell. Then, local densities of
LIM and LID sites as well as LIM and LID profiles
were determined for each nuclear shell as the subset
of voxels within a defined intensity range between
two thresholds measured separately for each channel
(MeC and DAPI): tbcg is the threshold value for the
background, and tQ, which separates high-amplitude
from low-amplitude intensities, as explicitly described
in [44]. All analytical findings related to image
processing including numerical results, MeC/DAPI
codistribution patterns, individual and combined
MeC/DAPI images, LIM/LID outputs of cells were
exported by means of a graphical user interface to
text or graphics files respectively for further statistical
analyzes. A built-in pseudo-coloring of KL divergence,
and LIM and LID site shading was superimposed onto
original images to facilitate visual reading and evaluation
of experimental data.
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The specificity and sensitivity of the applied anti-5-methyl-
cytosine antibody used in this study was assessed with a
test-microarray as shown in Figure 2. Antibody testing was
performed by an immunofluorescence assay utilizing a
custom made spotted microarray (Full Moon Biosystems)
comprising multiple copies of two synthesized 24-mer
oligonucleotide probes that were immobilized onto glass
microscopic slides: 50-TCGTTTTTTTTTTTTTTTTTT
CGT-30 (C-oligo) (MWG Biotech), and its counterpart 50-T
meCGTTTTTTTTTTTTTTTTTTmeCGT-30 (MeC-oligo)
(Biopolymers-Thermo Scientific), in which the two cytosine
molecules were replaced by methylcytosine. Immuno-
fluorescence was performed with the primary anti-
methylcytosine antibody and the Alexa488 conjugated sec-
ondary antibody, and alternatively a Cy3-conjugated goat
anti-mouse IgG1, using a denaturing step with hydrochloric
acid, a blocking step with 3% BSA in PBS, and stringency
washes as described for the in situ immunofluorescenceFigure 2 Specificity and sensitivity of used anti-methylcytosine antibo
immunofluorescence assay, in which the monoclonal anti-MeC antibody fo
with a secondary antibody (Cy3-conjugated anti-mouse IgG1 at 5 μg/ml), i
hybridized to a spotted array with two types of short 24-mer oligonucleoti
dinucleotides and its methylated counterpart, the MeC-oligo printed at var
numbers (1010–104) . Each DNA probe was spotted as octuple. The specific
shows best signal-to-noise (background and non-specific binding to unme
colored in green) decreases in a CpG copy number-dependent manner. (B
box in Figure 2A) of the same array was subjected to confocal scanning m
shows the more detailed intensity profile across the four different types ofassay above. Fluorescence detection was performed
comparatively at 5 microns resolution with a micro-
array scanner (G2565BA, Agilent Technologies)
equipped with a helium-neon laser (633 nm) to excite
Cy3, and the above-mentioned confocal microscope
with a Plan-Apo 10X 0.7 lens.
MethyLight assay for repetitive elements
MethyLight assays for measuring DNA methylation
content of Alu, Satα and Sat2 repeat sequences were
performed as previously described by Weisenberger et al.
[65]. Briefly, genomic DNA was extracted from
harvested Huh-7 cells and 1 μg of genomic DNA was
converted with bisulfite and recovered using the
Zymo EZ DNA methylation kit (Zymo Research,
Irvine, CA), as recommended by the manufacturer.
Aliquots of the bisulfite-converted DNAs were used
in separate MethyLight assays as previously described
[65]. MethyLight data specific for the three types ofdy. (A) The antibody properties were assessed by an indirect
r this study — used at the concentration of 1 μg/ml in combination
.e. at the same concentrations as in the cellular assay — was
des immobilized onto a glass slide: C-oligo that included two CG
ious dilutions that correlate with different approximate CpG copy
antibody, detected with a microarray scanner at 5 microns resolution,
thylated C-oligo) ratio at a copy number of 1010. The signal (false-
) Similar average intensities were obtained, when a sub-area (magenta
icroscopy at 200 nm horizontal resolution. The line scan (magenta)
spots and the intermediate gaps (coated glass slide/background).
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methylated reference (PMR).
Results
Zebularine exerts a comparably lower degree of
cytotoxicity than 5-azacytidine
We evaluated cultured DU145 prostate cancer cells and
Huh-7 hepatocellular carcinoma cell lines for imaging-
based DNA methylation analysis using the 3D-qDMI
system to determine DNA methylation phenotypes of
cells after 5-zacytidine and zebularine administration.
These drugs have been used with a variety of cancer cell
lines, including DU145 and Huh-7 cells, and described as
being compatible to a large extent with cell viability and cell
division [25,40,53-59]. The azanucleoside drug concentra-
tions applied here were in the range as previously reported
by investigations utilizing molecular nucleic acids-based
assays.
For cytotoxicity analysis, we tested cells that were
cultured in parallel to those used for imaging-based DNA
methylation analysis. Cytotoxicity analysis was divided
into an initial cell counting with an aliquot of trypsinized
cells, followed by staining of the remainder of the cells
with Annexin V and propidium iodide, and subsequent
flow cytometry. Zebularine was administered at molar
concentrations (8–1000 μM) that were one to two orders
of magnitude higher than AZA (0.5–20 μM) with compar-
able cytotoxic effects (Figure 3A, 3B). Therefore, ZEB can
be categorized as an agent with a much lower cytotoxic
potential. This has also been described in previous reports
[23,27]. In more detail, flow cytometry revealed a higher
sensitivity of DU145 for ZEB compared to Huh-7 cells:
IC10 and IC50 of ZEB were 8 μM and 500 μM, respectively
for DU145 versus 200 μM and 1000 μM for Huh-7. In the
case of AZA we experienced fewer discrepancies: IC10 was
0.5 μM for both cell types and IC50 was measured at
10 μM for DU145 and 5 μM for Huh-7. A greater than
two-fold increase of the apoptotic fraction (Annexin V-
positive) for AZA-treated cells of both types was detected
at 2.5 μM, and for ZEB-treated DU145 cells at 200 μM,
whereas same effects were registered in Huh-7 cells
at 1000 μM (Figures 3C and 3D). For the comparative
analysis of the two drugs at different concentrations,
2.5 × 105 cells were initially seeded onto coverslips.
After 72 hours we recorded a tripling of naïve cells
and only a doubling for both cell types at the drugs’
IC10 levels. Analogously, at IC50 ZEB-treated cells did
not show any population growth, whereas AZA-
treated cells showed significant reduction of their
populations: Huh-7 cells were reduced to 50% and
DU145 cells even to 10% of their original confluency.
The results underline the ability of ZEB to reduce
proliferation at higher doses without acting discern-
ibly cytotoxic as demonstrated by AZA.High variation in DNA demethylation and differential
drug sensitivity revealed by cell-by-cell imaging
Untreated cells as well as cells treated separately with
AZA and ZEB were automatically imaged from different
areas of each coverslip. Imaged sub-populations were
batch-processed off-line using 3D-qDMI software. We
evaluated drug action by measuring two parameters on a
per-cell basis: (i) the 5-methylcytosine load of nuclei,
which we refer to as the mean intensity of the MeC sig-
nal (IMeC), and (ii) the nuclear topology of the MeC ver-
sus DAPI signals. The number of cells that we could
extract the MeC-specific signals from depended on the
cytotoxicity level of the drugs: resulting in a certain
density of intact cells for each drug type, and subse-
quently the number of analyzable nuclei per image
frame. We determined IMeC across all resulting nuclei
for each drug type. Figure 4 illustrates relevant statistics
in naïve cells and each of the treated populations. The
mean intensity was evaluated by a two-sample
Kolmogorov-Smirnov test run for the experiments with
each combination of drug and cell line. In DU145 (ZEB)
cells, a significant difference was observed between all
distributions of IMeC, except for the 200 μM dose that
was not significantly different from 40 μM and 500 μM.
In DU145, cells treated with AZA the distributions of
IMeC for untreated and 0.5 μM were not significantly dif-
ferent. Also, no significant difference was observed be-
tween 10 μM and 20 μM in Huh-7 (AZA) cells, as well
as between untreated and 8 μM dose, and the three
highest concentrations in Huh-7 (ZEB) cells. The signifi-
cance level in each test (β) was determined by
Bonferroni correction (β = α/n) for α = 0.05, n = 6 or 7
for ZEB and AZA treatments, respectively.
The experimental results confirm the hypomethylating
effect of both drugs; the increase of drug concentration
causes a progressive loss of globally measured MeC-
specific signal in nuclei (IMeC) and a decrease of IMeC
spread (Figure 4). Interestingly, AZA, at the highest con-
centration applied (20 μM), reduced the IMeC stronger in
Huh-7 cells (88%) than in DU145 cells (75%), whereas
ZEB at the highest concentration (1000 μM) reduced
IMeC in DU145 cells at 72% versus 50% in Huh-7 cells,
on average. However, when comparing global DNA
methylation of cell nuclei at the equitoxic levels, ZEB
showed a much stronger DNA hypomethylation effect
than its nucleoside analogue at IC10 — 15% versus 5%
for DU145 and 43% versus 18% for Huh-7 — then a
milder effect at IC50: 54% versus 69% for DU145 and
50% versus 80% for Huh-7 cells. These results are in
agreement with previous studies [24,26,54], and under-
line the less toxic effect of zebularine on cells and the
milder nature of the drug when compared to AZA. In
other words, AZA-treatment in both cell lines showed
an approximate reduction of IMeC at 63% between IC10
Figure 3 Cytotoxicity of agents analyzed by FACS. Results for the comparative analysis of the effects of zebularine (A) and 5-azacytidine (B).
FL1-Height and FL2-Height represent Annexin V-staining and PI staining, respectively. Untreated control cell populations of DU145 and Huh-7
cells consist of a major portion of viable cells (> 90%). This reference profile changes with treatment of cells with different drug concentrations
applied for 72 hrs. The viability of cells was normalized against the viability in the control population (considered as 100%) and displayed as a
chart for zebularine (C) and 5-azacytidine (D).
Gertych et al. BMC Pharmacology and Toxicology 2013, 14:11 Page 7 of 21
http://www.biomedcentral.com/2050-6511/14/11
Figure 4 Normalized MeC mean intensity in untreated and drug-treated cells. Decline of signal intensity is plotted as a function of drug
concentration. Standard deviation of IMeC for untreated cells and cells treated with lower drug concentration is significantly greater than for cells
treated with higher drug concentration. Comparative reduction in overall DNA methylation (as percentage drop compared to untreated controls)
can be inferred for both drugs in DU145 cells, although at concentrations of one to two magnitudes lower for AZA than for ZEB. Huh-7 cells
show comparatively less loss of IMeC at highest zebularine concentration (1000 μM).
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leap was significantly different between ZEB-treated
cells: IMeC ≈ 39% for DU145 and only 7% for Huh-7 cells.
The data indicate that if DNA hypomethylation effects
would be influencing cytotoxicity, dose–response may
vary for different drugs in different cells.
Dose-dependent topological progression of DNA
hypomethylation correlates with cytotoxicity
The analysis of the MeC/DAPI codistribution showed a
high fraction of cells with pooled all similar categories in
response to both drugs for all concentrations (Figure 4).
ZEB-treated populations contained ≥ 90% similar cells,
compared with AZA-treated populations with an aver-
age ≥ 85% and a slight tendency to drop for DU145 cells
at 0.5 μM and 10 μM (82% and 79%, respectively). The
cell population heterogeneity analysis was performed
with an average total cell number of n = 300. Figure 5
displays normalized proportions of the two resultant
categories of cells, and example MeC/DAPI codistributions
are presented in Figure 6.
The effect of the drugs can be perceived as a reduction
in the MeC signal, with a similar effect in both cell
systems, when compared to nuclei of untreated cells. In
case of each drug, we observed a dose-dependent reduc-
tion of the MeC-specific signal. At lower drug
concentrations (ZEB: 8 μM and 40 μM; AZA: 0.5 μM
and 1 μM) the nucleus still shows significant DNA methy-
lation in its periphery, which becomes hypomethylated atmedium to higher drug doses (ZEB: 200–1000 μM, AZA:
5–20 μM). This is accompanied by a decrease of DNA
methylation at interior nuclear regions, gradually affecting
also DAPI-dense areas that are attributed to heterochro-
matin. Zebularine at the 1000 μM dose shows extremely
strong hypomethylation in the entire nuclear space, in-
cluding a large portion of heterochromatin in the nuclear
interior (Figure 5). In comparison, AZA shows similar
effects already at 5 μM (data not shown). These
observations support our findings presented in Figure 3.
The visual impressions of DNA hypomethylation in re-
sponse to drug type and concentration were confirmed by
quantitation of MeC and DAPI signal codistributions in
the respective nuclei and displayed as accompanying scat-
ter plots (Figure 6).
In addition to AZA-treatments, a subset of Huh-7 cells
was separately stained for covisualizing differential
spatial distribution of histone H3 lysine 9 trimethylation
(H3K9me3) and global DNA. H3K9me3 is associated
with heterochromatin and is involved in the recruitment
and binding of heterochromatin protein 1 (HP1), with
subsequent chromatin condensation and compaction
[66,67]. Therefore, we monitored this marker in sample
cells to specifically record changes in higher-order het-
erochromatin organization in conjunction with AZA
drug application (Figure 7). Our findings show a high
degree of colocalization between the H3K9me3 and
DAPI signals in untreated cells and cells treated with
the entire spectrum of applied AZA concentrations.
Figure 5 Cell population homogeneity measurement. Left diagram (different drugs): normalized proportions of the different cell populations
(n ≈ 300 is the number of cells analyzed for each category); untreated control cells show a high fraction (≥ 95%) of pooled similar cells (KL < 4.5);
this is true also for the majority of drug concentrations with both cell types (similarity on average≥ 90%); the lowest homogeneity values being
still relatively high at 82% for DU145/0.5 μM AZA and 79% for DU145/10 μM AZA. For simplification purposes, the rest of the cells were
summarized as dissimilar cells (KL≥ 4.5) in this display.
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utilized as a surrogate marker for visualizing changes of
global heterochromatin organization. Furthermore, it is
conceivable that a reduction in H3K9me3 could lead to
local DNA decondensation as extensively reported else-
where [10,68]. These findings support our topologic ap-
proach in using DAPI signals as a convenient way of
reporting changes in heterochromatin organization and
distribution, extensively discussed in previous works
[43,44]: as we found that DAPI staining is compatible
with the hydrochloric acid-treatment conditions of fixed
cells we applied for MeC-signal retrieval without any de-
tectable obscuring of both signals [64].
To further emboss the differential spatial distribution
of global DNA and its methylated portion, we focused
on the changes in the localization of LIMs and LIDs, as
subsets of nuclear signals that represent hypomethylated
sites and areas of lower DNA density in naïve and
treated cells. As illustrated in Figure 8, both LIM and
LID sites in the untreated cells have a rim-like localization
at or close to the nuclear border (LIM0.5 = 0.80–0.85, and
LID0.5 = 0.85) for both cell types after zebularine treat-
ment, while only 15–20% of LIMs were located in nuclei.
In cells comparatively treated with ZEB and AZA, the
nuclei showed an increased portion of interior LIMand LID sites after treatment with each drug. The
increase in LIM sites is correlated with the increase
in ZEB concentration: on average the LIM-portion in
DU145/Huh-7 is raised to ~30%/~40% at 8 μM, ~40%/
~40% at 40 μM, ~45%/~50% at 200 μM, 50%/60% at
500 μM, and ~55%/~65% at 1000 μM, respectively. In
comparison, the LID-portion in the nuclear interior
significantly expanded at lower ZEB concentrations: up to
50% at 8 μM for DU145 and 40% at 40 μM for Huh-7, but
did not significantly change beyond this concentration in
either cell type. In AZA-treated cells the change for LIDs
was very similar, however, LIM sites increased up to 60%
on average as can be inferred from the subset of data
displayed for the equitoxic drug concentrations in Figure 9.
For the two drugs, the responding distributions of LIM
and LID sites are quite similar between equitoxic
concentrations with a slight difference of IC50 for DU145
cells. Interestingly in this context, LID distributions did not
vary substantially compared to LIM distributions between
IC10 and IC50 concentrations. From these results we glean
that an increase of global DNA hypomethylation can be
traced in a dose-dependent manner. However, a significant
concurrent reorganization of the genome based on changes
in DAPI densities occurs already at the lower applied drug
concentrations, and does not seem to become stronger at
Figure 6 Global differential DNA methylation phenotypes in response to zebularine concentration. Maximum intensity projections (MIP)
of 3D-imaged nuclei of DU145 cells with high similarity values within their population category are selected for display (bars are 5 μm). Gradual
increase in reduction of MeC sites (false-colored green) was observed in correlation with an increase in zebularine concentration, similarly in both
cell types. At lower concentrations (8 and 40 μM) global demethylation seems to be preferentially stronger at the nuclear periphery (delineated
by DAPI, false-colored blue) and less DAPI-dense areas (supposedly euchromatin), and gradually affects more interior regions with increased drug
concentrations. At higher drug doses (200 μM and especially 500–1000 μM), also more DAPI-dense areas (heterochromatin) have been
demethylated. This latter effect is even more pronounced in the AZA-treated cell nuclei (data not shown in here). However, the majority of
heterochromatic regions seem to retain their compact conformation. The respective scatter plots of the nuclei provide more quantitative
information regarding changes in the MeC/DAPI codistribution as a consequence of drug application, especially for the lower drug doses: a
demethylation of non-heterochromatic sites (MeC-positive, low-DAPI signals) is indicated for 40 μM compared to 8 μM, as judged by the decline
of the graph slope. This trend correlates with increasing drug concentration. At 200–1000 μM the leveling of the slope towards the x-axis
becomes obvious; additionally also strong DAPI-positive sites (heterochromatin) have started to become hypomethylated.
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differential LIM and LID topology supplements the MeC/
DAPI codistribution findings described in Figure 6. The
respective diagrams of the cells show a flattening of MeC/
DAPI codistribution and the increase of LIM sites concur-
rent with increasing dosage. Stronger hypomethylating
effects at higher concentrations of AZA or ZEB were not
accompanied by an additional increase of LID sites. Also,
the increase in LIM distribution towards higher LIM
densities reflects the spatial progression of DNA
hypomethylation, which seems to positively correlate with
drug-based cytotoxicity.MeC/DAPI codistribution patterns are independent from
cell cycle interphases
Interphase cells are largely divided into two prominent
groups based on their cell cycle stage: G0/G1-phase and
G2-phase, differing in DNA content. Compared to
haploid G1-cells diploid G2-cells normally contain two
copies of the genome after having undergone the inter-
mediate S-phase, in which DNA is replicated. Therefore,
we investigated the possibility of existing differences in
MeC/DAPI distribution patterns between these two cell
cycle phases. DU145 cells were synchronized in culture
and arrested in G0/G1 and G2-phases. Cell stage-enriched
Figure 7 Nuclear codistribution of H3K9me3 and global DNA. Heterchromatin-associated H3K9me3 (red) significantly colocalizes with DAPI-
intense areas (blue) in untreated and AZA-treated Huh-7 cells. The scatter plots show that the signal in both channels gradually decreases with
increasing drug concentration. The relatively stable inclination of the colocalization graph indicates that both signals regress proportionally, which
could be interpreted as a tight correlation between heterochromatin and DAPI-intense regions.
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3-D imaging. We found that synchronized cell populations
were comprised of an absolute majority of cells in inter-
phase, as most of the barely attached and round metaphase
cells are usually lost during the early synchronization
steps (Figures 10A and 10B). Utilizing 3D-qDMI, we did
not detect any significant differences for MeC/DAPI
codistribution patterns between the two major cell cyclephases. Sample signatures of selected (similar) G1 and G2-
cells with a low KL-value that represent typical global nu-
clear MeC phenotypes are shown in Figure 10 (C–F), and
demonstrate similar codistribution patterns seen for un-
treated DU145 cells (Figure 5). Based on these results, we
conclude that significant changes in MeC/DAPI patterns
detected by 3D-qDMI are a result of drug action and not
influenced by eventual cell cycle phase variability.
Figure 8 Differential LIM and LID topology in zebularine-treated cells. LIM and LID sites detected in the range of (tbcg, tQ) in individual cells
from Figure 6 (marked in cyan color) are superimposed onto an intermediate optical section in the respective MeC (green) and DAPI (blue)
channels (left and middle columns). LIM/LID density curves obtained through morphological erosion of nuclei are shown as cumulative diagrams
(right column). These sites correspond with codistribution patterns in Figure 4 for the respective nuclei. The number of graph points in the third
column is associated with the number of detected shells; the value of each point refers to the fraction of all sites found in the nucleus up to the
next shell. V is the shell volume and Vtot is the total volume of a nucleus. The argument V/Vtot = 0.5 distinguishes all LIM sites that are localized in
the peripheral half of the nucleus from LIMs of the interior half (V/Vtot > 0.5). The diagonal line across each plot in represents hypothetically equal
density of LIM or LID sites across the nuclear volume. Similar degrees of high rim-like LIM and LID densities are apparent in untreated prostate
and hepatic cancer cell nuclei. LIM sites quasi-linearly expand towards the nuclear interior upon the increase of zebularine concentration, with
ZEB at 500–1000 μM show large coverage in Huh-7 nuclei and nearly full coverage throughout DU145 nuclei. Also LIDs show an increased
distribution in treated cells versus naïve cells, but the changes are more similar across all the applied ZEB and AZA concentrations in both cell
types, with most increases occurring in the exterior shells of the nuclei.
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Figure 9 Low-intesity MeC and low-intesity DAPI site distribution for equitoxic drug concentrations. For the two cell lines, the
responding distributions of LIM and LID sites are quite similar between equitoxic drug concentrations: LID distributions did not notably vary
between the two concentrations as much as LIM distributions did between IC10 and IC50 concentrations. However, a slight difference in LIM
distribution was measured for DU145 at IC50: at 500 μM LIM distribution seemed more similar to distribution at IC10.
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DAPI loads of nuclei in synchronized cell populations,
we found that the amplitude of the respective mean
intensities IMeC and IDAPI has nearly doubled in G2
versus G0/G1 phase. However, the distribution of these
two values shows a large spread in both phases
(Figure 11). This fact demonstrates that although we
could measure general load trends that most probably cor-
relate with the doubling of the genome between G1 and
G2 phases, overall mean intensities of global DNA and
total MeC content can drastically vary, even between
synchronized cells; therefore making it difficult to distin-
guish between their natural variation and strictly drug-
induced changes. On the contrary, when MeC/DAPI
codistribution data of the same G1 and G2 arrested cells
were combined, the computationally merged population
presented a high degree of homogeneity, as calculated by
KL-divergence measurement. This confirms the high simi-
larity between the MeC phenotypes of cells from the two
different populations, and emphasizes on the robustness of
MeC/DAPI patterns in evaluating drug-induced effects on
nuclear DNA methylation topology.
Analysis of DNA methylation levels in repeat sequences
correlates with imaging results
For comparative analysis of differential DNA methyla-
tion loads and to verify the quantitative accuracy of 3D-
qDMI, Huh-7 cells were subjected to AZA treatment
under the same conditions (concentrations and exposure
times) as for cells interrogated by image and flow
cytometry, and analyzed using MethyLight technology, areal-time PCR based DNA methylation assay [65].
MethyLight assays measuring DNA methylation of
repetitive element sequences have been previously
described as accurate surrogates for quantitating global
DNA methylation levels. Using this technique, we
measured DNA methylation levels in the three of the
most prevalent and highly methylated human repeat
sequences: the short interspersed nuclear element (SINE)
Alu sequences that are highly abundant in the human
genome, as well as the pericentromeric Sat2 and the
centromeric Satα, which both belong to constitutive
heterochromatin. The choice of said targets was based on
the facts that DNA hypomethylation of these sequences
can lead to local chromatin decondensation and genomic
instability, which have been well characterized in diverse
cancers and other types of complex traits such as ICF
syndrome [8,13,48]. Also, these repetitive elements have
been shown to become hypomethylated after exposure to
DNMTi [12-14,69]. The molecular assay revealed that
DNA methylation levels in all three classes of repetitive
elements showed similar trends and were in strong agree-
ment with results observed for global DNA methylation
with 3D-qDMI: the untreated cells record the highest level
of MeC content with a gradual decline as the drug
concentration increases, and a re-increase of DNA methyla-
tion for the 20 μM AZA dose. We believe that because of
the purportedly extensive damage to cell integrity at the
20 μM AZA concentration, the more methylated (possibly
drug-resistant) cells may have selectively survived
(Figure 12). This was observed with microscopic imaging,
in which the cell populations were significantly reduced
Figure 10 Cell cycle-specific MeC/DAPI codistribution patterns. Flow cytometry results show DU145 cell populations were efficiently arrested
in G0/G1-phase (A) and enriched in G2-phase (B). The culture conditions were chosen to skip an enrichment of the cells in S-Phase. G1-cells and
G2-cells from parallel populations were subjected to immunofluorescence and confocal imaging. The prototypic nuclei (C and D) of the two cell
cycle phases (with a low KL-value) show very similar MeC (green) and DAPI/gDNA (blue) codistribution patterns, also confirmed by their
respective scatter plots (E and F).
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numbers of highly methylated cells, which were excluded
as outliers in 3D-qDMI analysis.
In order to draw direct comparisons between image-
derived data and molecular sequenced-based results a
correlation coefficient was calculated between in situ
global DNA methylation levels, i.e. normalized MeC
mean intensities of analyzed Huh-7 cells (obtained by
3D-qDMI, Figure 4) and DNA methylation levels
measured (normalized PMR values) for each class of
repeat sequence across AZA concentrations up to the
10 μM dose, as shown in Table 1. The comparisonFigure 11 Variability of MeC and DAPI intensities in synchronized cel
global methylcytosine (MeC) and overall DNA (DAPI) nearly doubled betwe
signal distributions indicating high signal variabilities in synchronized cells.
data of the same cells from the two phases exposed a high degree of hom
between cells of the two phases.resulted in high correlations between the outcome of the
two platforms, the highest being for the interspersed Alu
sequences (R = 0.96), followed by pericentromeric Sat2
and centromeric Satα (R = 0.89 and 0.86, respectively).
Discussion
Epigenetic drugs including DNA methyltransferase
inhibitors, which are meant to correct for DNA methyla-
tion imbalances in cells, constitute promising therapeutic
approaches in the battle against cancer. The FDA-approved
azanucleotides 5-azacytidine and decitabine are already
administered to patients with hematologic neoplasias.ls. (A) Mean intensities (normalized for n = ~200 cells for each) of
en G0/G1-phase and G2-phase, with a large spread in MeC and DAPI
(B) In comparison MeC/DAPI codistribution patterns in the combined
ogeneity, which is a sign for high similarity in MeC phenotypes
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agents that has shown potentials for long-term oral
applications, as a result of systematic comparative analyses
[23-27,70,71]. However, most of the assessments have been
performed utilizing molecular methods that reveal precise
information regarding CpG methylation profiles of non-
repetitive sequences, but are currently costly and time-
consuming, if not challenged, when applied in a cell-by-cell
mode. Nevertheless, we believe that analysis of cultured cell
models at single-cell resolution is necessary to obtain a
more global and cell systemic picture of drug action and
efficacy in the search for new drugs as well as the epigenetic
evaluation of existing drugs. Thus, high-content and high-
throughput analyses, which have been supported by recent
advancements in imaging technology and computational
capacities, offer valuable means for rapid and cost-effective
cellular phenotyping in drug screening [72]. Furthermore,
the vast majority of studies so far have been focusing on
assessing the hypomethylating potential of drugs on
selected gene promoters in combination with cell viability
testing for drug cytotoxicity and genotoxicity. However,
hypomethylating agents can also perturb the epigenetic
regulation of chromatin conformation, thus having an
impact on the higher-order genome organization and
nuclear architecture that regulate genome integrity and
gene expression [19]. We were interested in tracking the
progression and extent of such global structural changes,
also in correlation with drug cytotoxicity to additionally
elaborate on the verification of the 3D-qDMI system’s
utility for the therapeutic field. Towards this end, we
have conducted a comparative cell-by-cell evaluation
of zebularine and its extensively characterized isoform
5-azacytidine based on their effects on global nuclear
DNA and its higher-order organization in the cell nu-
cleus. For the purpose of generating comparable topo-
logical data, we chose human cell culture models that
have rendered themselves as sensitive to both agents,
as well as cell culture conditions and drug doses that
have been used previously in comprehensive studies
to explore differential changes on the level of DNA
methylation for targeted single-copy CpG sites. Our
study includes standard viability testing for measuring
cytotoxicity and upgraded 3D-qDMI for evaluating
the demethylation effects on two levels: (i) changes in
the load of nuclear MeC (IMeC), and (ii) alterations in
the spatial codistribution of MeC and global DNA,
including condensed heterochromatin regions that are
represented by bright DAPI areas in the nuclei of
cells. Our cytotoxicity data as well as the results of
our topologic approach are strongly concordant with
data presented by other investigators [23,25,26,73-75].
Drug response efficacy, as judged by the degree of
spatial nuclear MeC/DAPI patterns, was comparably
high for the two drugs across all concentrations.In terms of cytotoxicity, we found that the Huh-7
hepatocarcinoma cells reacted more sensitively to
zebularine than the prostate cancer cells. Nevertheless,
for both cell types, zebularine elicited similar cytotoxicity
levels at doses that were one to two orders of magnitude
higher than for 5-azacytidine, thus can be considered as
much less cytotoxic at near-equimolar concentrations.
The results are in accordance with data from other
investigations that have probed the two agents in various
other cancer cell models such as bladder (T24), colon
(HCT-116), ovarian (A2780 and HEY) and breast
(MBA-MD-231 and MCF-7) cancer cell lines, as well
as in acute myeloid leukemia cells (AML 193)
[23,25,73-75]. Investigations addressing the chemistry
behind this phenomenon have led to cumulative evidence
indicating the formation of a permanent covalent bond
between human as well as selected bacterial DNMTs and
5-azacytidine that can trap the enzyme in a suicide
complex (triggering apoptosis). In comparison, only a
stable but no permanent covalent bond has been
proven between zebularine and the same DNMTs,
which would allow the enzymes’ release after binding
in vitro as well as in vivo. This may explain why
higher concentrations of zebularine are necessary for
similar levels of global DNA hypomethylation in cell
nuclei and its lower cytotoxicity (at equimolar
concentrations), compared with AZA [76,77].
Furthermore, we observed that the increase in cytotox-
icity correlates with global 5-methylcytosine levels, espe-
cially the extent of DNA hypomethylation at DAPI-
positive heterochromatic sites as revealed by 3D-qDMI
through scatter plotting of MeC/DAPI codistribution.
This was also true for AZA-treated cells (data not
shown). Along the same lines, when localizing low-
intensity MeC and DAPI sites in the same nuclei, we
could map the gradual increase in LIMs from the
nuclear periphery into the more interior parts of the
nuclei. However, we experienced that a strong level of
LID increase within the nuclei interior was already seen
at the lower zebularine concentration (8–40 μM),
compared to naïve cells, which did not significantly
change up to the highest concentration applied
(1000 μM). These LID-patterns were very similar to the
one in AZA-treated cells (Figure 8), in which the major-
ity of LIDs were found to be located in the nuclear per-
iphery. These conclusions are drawn from images of
cells with seemingly intact nuclear envelope. In fact,
for drug concentrations ≥5 μM for 5-azacytidine and
≥500 μM for zebularine, a large number of cells were
found to present DAPI and MeC signals outside of
their nuclei, leading to the assumption that the drugs
had also affected the nuclear envelope and caused
DNA leakage. In these cells the respective LID curves
were located below the diagonal of the graphs (not
Figure 12 Drug-induced changes in DNA methylation levels of repetitive elements. DNA methylation levels of the three classes of repeat
sequences Alu, Satα, and Sat2, assessed by specific MethyLight assays, significantly decreased in Huh-7 cells upon treatment with AZA. The
degree of hypomethylation correlated with drug concentration, with the exception of an increase in DNA methylation seen for all three repetitive
elements at the 20 μM AZA concentration.
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Table 1 Correlation between imaging and sequence-based methylcytosine levels
3D-qDMI MethyLight
AZA concentration Normalized MeC intensity Normalized Alu PMR value Normalized Sat2 PMR value Normalized Satα PMR value
No Drug 1.00 1.00 1.00 1.00
0.5 μM 0.72 0.92 0.86 0.37
1 μM 0.34 0.49 0.65 0.20
2.5 μM 0.26 0.51 0.69 0.42
5 μM 0.20 0.31 0.31 0.15
10 μM 0.14 0.17 0.45 0.22
20 μM 0.13 0.61 0.58 0.88
Correlation coefficient R* 0.96 0.89 0.86
* Correlation coefficient R was calculated between the normalized MeC intensities measured by 3D-qDMI and normalized PMR values of the three classes of
repetitive elements obtained by MethyLight, excluding the values for 20 μM of AZA.
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drug concentrations, such cells were not included in
our further analyses.
Therefore we cannot exclude any contribution of topo-
logical changes of gDNA/heterochromatin to cytotox-
icity. On the contrary, we assume that global DNA
demethylation may lead to both DNA hypomethylation
as well as gDNA reorganization, which are bilateral and
together could lead to cellular decline. Although, our
data here suggest that cytotoxicity is more fine-
correlated with DNA hypomethylation than with bulk
DNA reorganization. However, it may also be possible
that only local gDNA rearrangements occurred under
the conditions applied in our study. The latter effect is
conceivable from the increase of LIMs in nuclear areas
that harbor heterochromatin: as a significant LIM increase
was detected for cells already at low zebularine doses, a
compounding of both DNA demethylation effects may
have triggered cellular disruption. Figure 6 underlines
the fact that 5-azacytidine has equivalent effects at
concentrations that are much lower than of zebularine.
The mode of action of azanucleosides is quite complex
[78]. Cytosine hypomethylation by azanucleosides, includ-
ing zebularine, has been extensively reported to reactivate
tumor suppressor genes and apoptosis-related genes
[79-81] but also the relaxation of highly compacted chro-
matin that can be seen as a loss of gDNA (DAPI) signal per
voxel [43,44], as chromatin conformation is linked to DNA
methylation and its bilateral relationship to histone tail
modifications [82]. Therefore, we believe that cell-by-cell
topological analysis as used in our approach, i.e. the
topology of LIMs and LIDs in combination with the display
of differential MeC/DAPI colocalization patterns shows a
potential to serve as a valuable indicator for the observed
phenomena: cytotoxicity-correlated global DNA hypome-
thylation and DNA reorganization, as consequences of drug
effects. For the selected combinations of cell types and
agents, the measurement of mean MeC signal (IMeC) — aderivative of DNA methylation load, across all imaged
cells — corresponded well with the level of cytotoxicity
(Figure 4). However, for the majority of cases IMeC
presented a relatively high standard deviation, whereas for
the same cell populations we observed a low fraction of
dissimilar cells in terms of MeC/gDNA distribution
(Figure 5). The discrepancy between the two signatures
becomes more plausible with the analysis of synchronized
DU145 cells: high similarity was measured between G0/
G1-cells and G2-cells in MeC/DAPI codistribution
(Figure 10). On the contrary, individual intensity values for
global 5-methylcytosine (MeC) and overall DNA (DAPI)
nearly doubled between G0/G1-phase and G2-phase as
expected, although with a large spread in both signal
distributions indicating high signal variability even in
synchronized cells (Figure 11). Based on these findings, we
believe that signatures based on spatial MeC/DAPI
codistribution are more robust in MeC-phenotyping of cells
than simply measuring DNA methylation loads, as they can
better distinguish between drug-induced demethylation
effects and the variation of methylation among individual
cells. In combination with K-L divergence measurement,
such a cell-by-cell cross-examination as performed with
3D-qDMI can provide structure-based quantities for
studying epigenetic drug response.
Finally, in order to test the quantitative accuracy of 3D-
qDMI a comparative analysis was performed utilizing
MethyLight assays that have been specifically designed for
and proven to measure differential levels of DNA methyla-
tion in repeat sequences such as Alu, Sat2, and Satα with
high confidence [65]. These sequences are highly
methylated in human cells and also represent a significant
portion of their genomes. Therefore, they have been proven
to serve as surrogates for measuring the global content of
5-methylcytosine in cells. Our comparative analyses
revealed a significantly high degree of correlation between
the outcomes of the two methods. We chose MethyLight
as a validated technique over high-pressure liquid
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measuring global DNA methylation: as the latter method
requires significantly more input DNA (5–10 μg).
We conclude that the results of our work strongly
support the idea of utilizing the spatial higher-order
genome organization as a sentinel for drug-induced toxicity
effects in liaison with global DNA hypomethylation. In
particular, nuclear DNA methylation distribution patterns
have proven to serve as an indicator of topological changes
of the genome that could perturb spatial interactions of
genomic loci and subsequent expression programs leading
to cytotoxicity in treated cells. This is quite conceivable as
it has been observed that DNA hypomethylation after treat-
ment with DNMTi can be accompanied by additional
changes in histone-tail modifications and nucleosome
depletion that decrease DNA-repressive mechanisms and
support a more open chromatin conformation [83-86], an
effect that we could reconcile with 3D image analysis for
H3K9me3. A decrease in this repressive and compacting
chromatin landmark with increasing doses of 5-azacytidine
correlates well with a decrease in gDNA signal, and could
be interpreted as chromatin decondensation (Figure 7).
These downstream effects remain to be evaluated by deter-
mining the underlying molecular effects of possible cellular
reprogramming, including the degree of heterochromatin
demethylation [87]. Especially, the loss of global DNA
methylation at heterochromatic areas of the genome that
harbor highly repetitive DNA sequences such as highly
abundant Alu repeats, transposable long interspersed nu-
clear elements (LINEs) and satellite DNAs can be
associated with multiple risks towards genome instability
[8,88]; through an adverse reorganization of the genome
with side effects, such as transcriptional activation of
oncogenes, activation of latent retrotransposons, chromo-
somal instability, and telomere elongation of chromosomes
[11,89-92]. More specifically, Satα and Sat2 DNA
hypomethylation may favor centromeric and pericen-
tromeric instability, respectively. Alu retroelements, if left
unchecked, would insert throughout the genome into non-
coding and coding regions. The result would be mutations,
and activation of oncogenes: spontaneous insertion of an
Alu element causes nearby promoters to be hypome-
thylated, increasing gene expression [93,94]. Diseases
directly associated with Alu insertion into coding regions
include neurofibromatosis, haemophilia, agammaglobulin-
aemia, leukemia, breast cancer and ovarian cancer [95].
Any malignancy caused by Alu insertion is both heritable
along somatic cell lines as well as in the germline. This
concern has been recently strengthened by observations, in
which specific genomic areas were found to become re-
methylated during a following DNA replication step after
initial drug-induced demethylation; as a possible mechan-
ism to protect these sequences from permanent
hypomethylation [96]. The study showed that exposure ofcancer cells to agents such as 5-azacytidine and decitabine
preferentially led to demethylation of CpGs not
located in CpG-islands, whereas island-associated
CpGs became preferentially re-methylated, suggesting
that CG-dinucleotides in repetitive elements could be-
come more persistently hypomethylated than gene-
associated CGs.Conclusions
In light of these observations, it appears reasonable to
point out the necessity of new assays and complementary
bioinformatics for detecting unwanted genomic-scale
adverse effects such as heterochromatin reorganization,
that could be used as endpoints in the cytotoxic and
genotoxic risk assessment of already existing demethylating
drugs and next-generation chromatin-targeting agents
under development. Recent advancements in cellular
imaging and computational image analysis have made it
feasible for large volumes of images from thousands of cells
to be analyzed in relatively short amount of time at
substantially lower costs. Imaging-based cytomics also
enables the quantification of spatial and temporal distribu-
tion of molecules and cellular components within their
native environment [97], which can boost understanding
drug activity at the cell systemic level. Within this context,
MeC phenotyping appears to provide a valuable technology,
and further investigations will be crucial to evaluate its
performance for a broader spectrum of epigenetic drugs in
cytotoxicity and eventually genotoxicity testing. Hence, the
combination of 3D-qDMI with comparative techniques that
provide genome-wide sequence-specific MeC-profiles and
detail concurrent changes in chromatin conformation could
lead to validation of MeC phenotypes in assessment of
drug-induced chromatin states. A variety of impressive
high-resolution sequencing-based techniques have recently
become available such as NOMe-Seq [39], which provides
nucleosome positioning landscapes; chromosome
conformation capture (3C) methodology and its whole-
genomic version Hi-C, which map the 3D architecture of
the genome by proximity-based ligation and subsequent
next-generation sequencing [98,99]; a related method
called chromatin interaction analysis using paired-end
tag sequencing (ChIA–PET) [100], and newer attempts
that focus on increasing the sensitivity of chromatin
immunoprecipitation-based assays towards single-cell
analysis [101]. For example: the correlation of chromatin
textures derived from MeC patterns with matching nucleo-
some depleted regions and proximity-ligation profiles can
lead to the identification of MeC phenotypes indicative of
risky and genotoxic drug effects.
Abbreviations
CSMC: Cedars-Sinai Medical Center; Cy3: Cyanine 3; FBS: Fetal bovine serum;
IC10: Inhibitory concentration at which 10% of cells are nonviable.
Gertych et al. BMC Pharmacology and Toxicology 2013, 14:11 Page 19 of 21
http://www.biomedcentral.com/2050-6511/14/11Competing interest
The authors declare that they have no competing interests.
Authors’ contributions
JT designed and conducted the study, and performed all drug experiments.
JHO contributed with cell synchronization assays. KAW performed imaging.
AG and JT conceptualized image analyses. AG contributed analytical
software tools. AG and JT performed image and statistical data analysis. JT
wrote the manuscript together with AG. DJW was in charge of the
comparative MethyLight assays and helped with manuscript revision. All
authors read and approved the final manuscript.
Acknowledgements
We thank Patricia Lin (CSMC Research Flow Cytometry Core) for helping us
with flow cytometry and Vaithilingaraja Arumugaswami (CSMC) for Huh-7
cells. This work was supported by the DOD-CDMRP Award W81XWH-10-1-
0939 (to JT), the NIH grant 1R21CA143618-01A1 (to AG), and institutional
grants from the Department of Surgery at CSMC.
Author details
1Translational Cytomics Group, Department of Surgery, Cedars-Sinai Medical
Center, Los Angeles, CA 90048, USA. 2Chromatin Biology Laboratory,
Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA 90048,
USA. 3Bioinformatics Laboratory, Department of Surgery, Cedars-Sinai Medical
Center, Los Angeles, CA 90048, USA. 4Department of Biomedical Sciences,
Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. 5USC Epigenome
Center, Keck School of Medicine, University of Southern California, Los
Angeles, CA 90089, USA.
Received: 20 June 2012 Accepted: 14 January 2013
Published: 11 February 2013
References
1. Jaenisch R, Bird A: Epigenetic regulation of gene expression: how the
genome integrates intrinsic and environmental signals. Nat Genet 2003,
33:245–254.
2. Jones PA, Baylin SB: The epigenomics of cancer. Cell 2007, 128:683–692.
3. Herman JG, Baylin SB: Gene silencing in cancer is associated with
promoter hypermethylation. N Engl J Med 2003, 349:2042–2054.
4. Esteller M: Epigenetics in cancer. N Engl J Med 2008, 358:1148–1159.
5. Costello JF, Frühwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X,
Wright FA, Feramisco JD, Peltomäki P, Lang JC, Schuller DE, Yu L, Bloomfield
CD, Caligiuri MA, Yates A, Nishikawa R, Su Huang H, Petrelli NJ, Zhang X,
O’Dorisio MS, Held WA, Cavenee WK, Plass C: Aberrant CpG-island
methylation has non-random and tumour-type-specific patterns. Nat
Genet 2000, 24:132–138.
6. Ehrlich M, Gama-Sosa MA, Huang LH, Midgett RM, Kuo KC, McCune RA,
Gehrke C: Amount and distribution of 5-methylcytosine in human DNA
from different types of tissues of cells. Nucleic Acids Res 1982, 10:2709–2721.
7. Gardiner-Garden M, Frommer M: CpG islands in vertebrate genomes.
J Mol Biol 1987, 196:261–282.
8. Ehrlich M: DNA Hypomethylation in cancer cells. Epigenomics 2009,
1:239–259.
9. Puitri EL, Robertson KD: Epigenetic mechanisms and genome stability.
Clin Epigenetics 2011, 2:299–314.
10. Peng JC, Karpen GH: Epigenetic regulation of heterochromatic stability.
Curr Opin Genet Dev 2008, 18:204–211.
11. Feinberg AP, Vogelstein B: Hypomethylation distinguishes genes of some
human cancers from their normal counterparts. Nature 1983, 301:89–92.
12. Gama-Sosa MA, Slagel VA, Trewyn RW, Oxenhandler R, Kuo KC, Kuo KC,
Gehrke CW, Ehrlich M: The 5-methylcytosine content of DNA from human
tumors. Nucleic Acid Res 1983, 11:6883–6894.
13. Ehrlich M: NA hypomethylation and cancer. In DNA Alterations in Cancer:
Genetic and Epigenetic Changes. Edited by Ehrlich M. Natick, MA: Eaton
Publishing; 2000:273–291.
14. Dunn BK: Hypomethylation: one side of a larger picture. Ann N Y Acad Sci
2003, 983:28–42.
15. Fraser P, Bickmore W: Nuclear organization of the genome and the
potential for gene regulation. Nature 2007, 447:413–417.
16. Deal RB, Henikoff S: Capturing the dynamic epigenome. Genome Biol 2010,
11:218.17. Misteli T: Higher-order genome organization in human disease. Cold
Spring Harb Perspect Biol 2010, 2:a000794.
18. Li G, Reinberg D: Chromatin higher-order structures and gene regulation.
Curr Opin Genet Dev 2011, 21:175–186.
19. Tajbakhsh J: DNA methylation topology: potential of a chromatin
landmark for epigenetic drug toxicology. Epigenomics 2011,
3:761–770.
20. Yoo CB, Jones PA: Epigenetic therapy of cancer: past, present and future.
Nat Rev Drug Discov 2006, 5:37–50.
21. Gore SD, Jones C, Kirkpatrick P: Decitabine. Nat Rev Drug Discov 2006,
5:891–892.
22. Issa JP, Kantarjian H: 5-azacytidine. Nat Rev Drug Discov 2005, (Suppl):S6–S7.
23. Cheng JC, Matsen CB, Gonzales FA, Ye W, Greer S, Marquez VE, Jones PA,
Selker EU: Inhibition of DNA methylation and reactivation of silenced
genes by zebularine. J Natl Cancer Inst 2003, 95:399–409.
24. Yoo CB, Cheng JC, Jones PA: Zebularine: a new drug for epigenetic
therapy. Biochem Soc Trans 2004, 32:910–912.
25. Marquez VE, Kelley JA, Agbaria R, Ben-Kasus T, Cheng JC, Yoo CB, Jones PA:
Zebularine: a unique molecule for an epigenetically based strategy in
cancer chemotherapy. Ann N Y Acad Sci 2005, 1058:246–254.
26. Herranz M, Martín-Caballero J, Fraga MF, Ruiz-Cabello J, Flores JM, Desco M,
Marquez V, Esteller M: The novel DNA methylation inhibitor zebularine is
effective against the development of murine T-cell lymphoma. Blood
2006, 107:1174–1177.
27. Stresemann C, Bokelmann I, Mahlknecht U, Lyko F: 5-azacytidine causes
complex DNA methylation responses in myeloid leukemia. Mol Cancer
Ther 2008, 7:2998–3005.
28. Santi DV, Norment A, Garrett CE: Covalent bond formation between a
DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc
Natl Acad Sci USA 1984, 81:6993–6997.
29. Bender CM, Gonzalgo ML, Gonzales FA, Nguyen CT, Robertson KD, Jones
PA: Roles of Cell Division and Gene Transcription in the Methylation of
CpG Islands. Mol Cell Biol 1999, 19:6690–6698.
30. Weisenberger DJ, Velicescu M, Cheng JC, Gonzales FA, Liang G, Jones PA:
Role of the DNA Methyltransferase Variant DNMT3b3 in DNA
Methylation. Mol Cancer Res 2004, 2:62–72.
31. Ghoshal K, Datta J, Majumder S, Bai S, Kutay H, Motiwala T, Jacob ST: 5-Aza-
Deoxycytidine Induces Selective Degradation of DNA Methyltransferase
1 by a Proteasomal Pathway That Requires the KEN Box, Bromo-
Adjacent Homology Domain, and Nuclear Localization Signal. Mol Cell
Biol 2005, 25:4727–4741.
32. Zhu WG, Hileman T, Ke Y, Wang P, Lu S, Duan W, Dai Z, Tong T, Villalona-
Calero MA, Plass C, Otterson GA: 5-aza-20-deoxycytidine activates the p53/
p21Waf1/Cip1 pathway to inhibit cell proliferation. J Biol Chem 2004,
279:15161–15166.
33. Yang X, Noushmehr H, Han H, Andreu-Vieyra C, Liang G, Jones PA: Gene
reactivation by 5-aza-20-deoxycytidine-induced demethylation requires
SRCAP-mediated H2A.Z insertion to establish nucleosome depleted
regions. PLoS Genet 2012, 8:e1002604.
34. Patra SK, Patra A, Rizzi F, Ghosh TC, Bettuzzi S: Demethylation of (Cytosine-
5-C-methyl) DNA and regulation of transcription in the epigenetic
pathways of cancer development. Cancer Metastasis Rev 2008,
27:315–334.
35. Patra SK, Bettuzzi S: Epigenetic DNA-(cytosine-5-carbon) modifications: 5-
aza-20-deoxycytidine and DNA-demethylation. Biochemistry (Mosc) 2009,
74:613–619.
36. Ammerpohl O, Martin-Subero JI, Richter J, Vater I, Siebert R: Hunting for the
5th base: Techniques for analyzing DNA methylation. Biochim Biophys
Acta 2009, 1790:847–862.
37. Laird PW: Principles and challenges of genome-wide DNA methylation
analysis. Nat Rev Genet 2010, 11:191–203.
38. Fatemi M, Pao MM, Jeong S, Gal-Yam EN, Egger G, Weisenberger DJ, Jones
PA: Footprinting of mammalian promoters: use of a CpG DNA
methyltransferase revealing nucleosome positions at a single molecule
level. Nucleic Acids Res 2005, 33:e176.
39. Kelly TK, Liu Y, Lay FD, Liang G, Berman BP, Jones PA: Genome-wide
mapping of nucleosome positioning and DNA methylation within
individual DNA molecules. Genome Res 2012, 22:2497–2506.
40. Haaf T: The effects of 5-azacytidine and 5-azadeoxycytidine on
chromosome structure and function: implications for methylation-
associated cellular processes. Pharmacol Ther 1995, 65:19–46.
Gertych et al. BMC Pharmacology and Toxicology 2013, 14:11 Page 20 of 21
http://www.biomedcentral.com/2050-6511/14/1141. De Capoa A, Menendez F, Poggesi I, Giancotti P, Grappelli C, Marotta MR, Di
Leandro M, Reynaud C, Niveleau A: Cytological evidence for 5-azacytidine
-induced demethylation of the heterochromatic regions of human
chromosomes. Chromosome Res 1996, 4:271–276.
42. Tajbakhsh J, Wawrowsky KA, Gertych A, Bar-Nur O, Vishnevsky E, Lindsley
EH, Farkas DL: Characterization of tumor cells and stem cells by
differential nuclear methylation imaging. In Imaging, Manipulation, and
Analysis of Biomolecules, Cells, and Tissues. Proceedings of the SPIE: 19–24
January 2008. Edited by Farkas DL DL, Nicolau DV, Robert C, Leif RC. San
Jose, CA: SPIE Publications; 2008:6859F1–6859F10.
43. Gertych A, Wawrowsky KA, Lindsley E, Vishnevsky E, Farkas DL, Tajbakhsh J:
Automated quantification of DNA demethylation effects in cells via 3D
mapping of nuclear signatures and population homogeneity
assessment. Cytometry A 2009, 75:569–583.
44. Gertych A, Farkas DL, Tajbakhsh J: Measuring topology of low-intensity
DNA methylation sites for high-throughput assessment of
epigenetic drug-induced effects in cancer cells. Exp Cell Res 2010,
316:3150–3160.
45. Szyf M: Epigenetics, DNA methylation, and chromatin modifying drugs.
Annu Rev Pharmacol Toxicol 2009, 49:243–263.
46. Tajbakhsh J, Gertych A, Farkas DL: Utilizing nuclear DNA methylation
patterns in cell-based assays for epigenetic drug screening. Drug
Discovery World 2010, 27–35. spring edition.
47. Tong WG, Wierda WG, Lin E, Kuang SQ, Bekele BN, Estrov Z, Wei Y, Yang H,
Keating MJ, Garcia-Manero G: Genome-wide DNA methylation profiling of
chronic lymphocytic leukemia allows identification of epigenetically
repressed molecular pathways with clinical impact. Epigenetics 2010,
5:499–508.
48. Ehrlich M: DNA hypomethylation, cancer, the immunodeficiency,
centromeric region instability, facial anomalies syndrome and
chromosomal rearrangements. J Nutr 2002, 132:2424S–2429S.
49. Espada J, Esteller M: Epigenetic control of nuclear architecture. Cell Mol
Life Sci 2007, 64:449–457.
50. Santos AP, Abranches R, Stoger E, Beven A, Viegas W, Shaw PJ: The
architecture of interphase chromosomes and gene positioning are
altered by changes in DNA methylation and histone acetylation. J Cell Sci
2002, 115:4597–4605.
51. Gilbert N, Thomson I, Boyle S, Allan J, Ramsahoye B, Bickmore WA: DNA
methylation affects nuclear organization, histone modifications, and
linker histone binding but not chromatin compaction. J Cell Biol 2007,
177:401–411.
52. Christman JK: 5-azacytidine and 5-aza-20-deoxycytidine as inhibitors of
DNA methylation: mechanistic studies and their implications for cancer
therapy. Oncogene 2002, 21:5483–5495.
53. Stresemann C, Brueckner B, Musch T, Stopper H, Lyko F: Functional
diversity of DNA methyltransferase inhibitors in human cancer cell lines.
Cancer Res 2006, 66:2794–2800.
54. Dote H, Cerna D, Burgan WE, Carter DJ, Cerra MA, Hollingshead MG,
Camphausen K, Tofilon PJ: Enhancement of in vitro and in vivo tumor cell
radiosensitivity by the DNA methylation inhibitor zebularine. Clin Cancer
Res 2005, 11:4571–4579.
55. Schwarze SR, Fu VX, Desotelle JA, Kenowski ML, Jarrard DF: The
identification of senescence-specific genes during the induction of
senescence in prostate cancer cells. Neoplasia 2005, 7:816–823.
56. Ewald J, Desotelle J, Almassi N, Jarrard D: Drug-induced senescence
bystander proliferation in prostate cancer cells in vitro and in vivo. Br J
Cancer 2008, 98:1244–1249.
57. Patra A, Deb M, Dahiya R, Patra SK: 5-Aza-20-deoxycytidine stress response
and apoptosis in prostate cancer. Clin Epigenetics 2011, 2:339–348.
58. Venturelli S, Armeanu S, Pathil A, Hsieh CJ, Weiss TS, Vonthein R, Wehrmann
M, Gregor M, Lauer UM, Bitzer M: Epigenetic combination therapy as a
tumor-selective treatment approach for hepatocellular carcinoma. Cancer
2007, 109:2132–2141.
59. Andersen JB, Factor VM, Marquardt JU, Raggi C, Lee YH, Seo D, Conner EA,
Thorgeirsson SS: An integrated genomic and epigenomic approach
predicts therapeutic response to zebularine in human liver cancer. Sci
Transl Med 2010, 2:54ra77.
60. Heinemann L, Simpson GR, Annels NE, Vile R, Melcher A, Prestwich R,
Harrington KJ, Pandha HS: The effect of cell cycle synchronization
on tumor sensitivity to reovirus oncolysis. Mol Ther 2010,
18:2085–2093.61. Whitfield ML, Zheng LX, Baldwin A, Ohta T, Hurt MM, Marzluff WF: Stem-
loop binding protein, the protein that binds the 30 end of histone
mRNA, is cell cycle regulated by both translational and posttranslational
mechanisms. Mol Cell Biol 2000, 20:4188–4198.
62. Wong C, Stearns T: Mammalian cells lack checkpoints for tetraploidy,
aberrant centrosome number, and cytokinesis failure. BMC Cell Biol 2005, 6:6.
63. van Engeland M, Nieland LJ, Ramaekers FC, Schutte B, Reutelingsperger CP:
Annexin V-affinity assay: a review on an apoptosis detection system
based on phosphatidylserine exposure. Cytometry 1998, 31:1–9.
64. Tajbakhsh J, Gertych A: Three-dimensional quantitative DNA methylation
imaging for chromatin texture analysis in pharmacoepigenomics and
toxicoepigenomics. In Epigenomics: From Chromatin Biology to Therapeutics.
Edited by Appasani K. Cambridge, UK: Cambridge University Press; 2012:273.
65. Weisenberger DJ, Campan M, Long TI, Kim M, Woods C, Fiala E, Ehrlich M,
Laird PW: Analysis of repetitive element DNA methylation by MethyLight.
Nucleic Acids Res 2005, 33:6823–6836.
66. Cowell IG, Aucott R, Mahadevaiah SK, Burgoyne PS, Huskisson N, Bongiorni
S, Prantera G, Fanti L, Pimpinelli S, Wu R, Gilbert DM, Shi W, Fundele R,
Morrison H, Jeppesen P, Singh PB: Heterochromatin, HP1 and methylation
at lysine 9 of histone H3 in animals. Chromosoma 2002, 111:22–36.
67. Lachner M, O’Carroll D, Rea S, Mechtler K, Jenuwein T: Methylation of
histone H3 lysine 9 creates a binding site for HP1 proteins. Nature 2001,
410:116–120.
68. Peng JC, Karpen GH: Heterochromatic genome stability requires
regulators of histone H3 K9 methylation. PLoS Genet 2009, 5:e1000435.
69. Shvachko LP: Alterations of constitutive pericentromeric heterochromatin
in lymphocytes of cancer patients and lymphocytes exposed to 5-
azacytidine is associated with hypomethylation. Exp Oncol 2008, 30:230–234.
70. Chiam K, Centenera MM, Butler LM, Tilley WD, Bianco-Miotto T: GSTP1 DNA
methylation and expression status is indicative of 5-aza-20-deoxycytidine
efficacy in human prostate cancer cells. PLoS One 2011, 6:e25634.
71. Chen M, Shabashvili D, Nawab A, Yang SX, Dyer LM, Brown KD,
Hollingshead M, Hunter KW, Kaye FJ, Hochwald SN, Marquez VE, Steeg P,
Zajac-Kaye M: DNA methyltransferase inhibitor, zebularine, delays tumor
growth and induces apoptosis in a genetically engineered mouse model
of breast cancer. Mol Cancer Ther 2012, 11:370–382.
72. Lang P, Yeow K, Nichols A, Scheer A: Cellular imaging in drug discovery.
Nat Rev Drug Discov 2006, 5:343–356.
73. Cheng JC, Weisenberger DJ, Gonzales FA, Liang G, Xu GL, Hu YG, Marquez
VE, Jones PA: Continuous zebularine treatment effectively sustains
demethylation in human bladder cancer cells. Mol Cell Biol 2004,
24:1270–1278.
74. Scott SA, Lakshimikuttysamma A, Sheridan DP, Sanche SE, Geyer CR, Hu YG,
Marquez VE, Jones PA: Zebularine inhibits human acute myeloid leukemia
cell growth in vitro in association with p15INK4B demethylation and
reexpression. Exp Hematol 2007, 35:263–273.
75. Billam M, Sobolewski MD, Davidson NE: Effects of a novel DNA
methyltransferase inhibitor zebularine on human breast cancer cells.
Breast Cancer Res Treat 2010, 120:581–592.
76. van Bemmel DM, Brank AS, Eritja R, Marquez VE, Christman JK: DNA
(Cytosine-C5) methyltransferase inhibition by oligodeoxyribonucleotides
containing 2-(1H)-pyrimidinone (zebularine aglycon) at the enzymatic
target site. Biochem Pharmacol 2009, 78:633–641.
77. Champion C, Guianvarc’h D, Sénamaud-Beaufort C, Jurkowska RZ, Jeltsch A,
Ponger L, Arimondo PB, Guieysse-Peugeot AL: Mechanistic insights on the
inhibition of c5 DNA methyltransferases by zebularine. PLoS One 2010,
5:e12388.
78. Stresemann C, Lyko F: Modes of action of the DNA methyltransferase
inhibitors 5-azacytidine and decitabine. Int J Cancer 2008, 123:8–13.
79. Huang J, Plass C, Gerhauser C: Cancer chemoprevention by targeting the
epigenome. Curr Drug Targets 2011, 12:1925–1956.
80. Khan R, Schmidt-Mende J, Karimi M, Gogvadze V, Hassan M, Ekström TJ,
Zhivotovsky B, Hellström-Lindberg E: Hypomethylation and apoptosis in
5-azacytidine-treated myeloid cells. Exp Hematol 2008, 36:149–157.
81. Ruiz-Magaña MJ, Rodríguez-Vargas JM, Morales JC, Saldivia MA, Schulze-
Osthoff K, Ruiz-Ruiz C: The DNA methyltransferase inhibitors zebularine
and decitabine induce mitochondria-mediated apoptosis and DNA
damage in p53 mutant leukemic T cells. Int J Cancer 2012, 130:1195–1207.
82. D’Alessio AC, Szyf M: Epigenetic tête-à-tête: the bilateral relationship
between chromatin modifications and DNA methylation. Biochem Cell
Biol 2006, 84:463–476.
Gertych et al. BMC Pharmacology and Toxicology 2013, 14:11 Page 21 of 21
http://www.biomedcentral.com/2050-6511/14/1183. Nguyen CT, Weisenberger DJ, Velicescu M, Gonzales FA, Lin JC, Liang G,
Jones PA: Histone H3-lysine 9 methylation is associated with aberrant
gene silencing in cancer cells and is rapidly reversed by 5-aza-20-
deoxycytidine. Cancer Res 2002, 62:6456–6461.
84. Lin JC, Jeong S, Liang G, Takai D, Fatemi M, Tsai YC, Egger G, Gal-Yam EN,
Jones PA: Role of nucleosomal occupancy in the epigenetic silencing of
the MLH1 CpG island. Cancer Cell 2007, 12:432–444.
85. Komashko VM, Farnham PJ: 5-azacytidine treatment reorganizes genomic
histone modification patterns. Epigenetics 2010, 5:229–240.
86. Si J, Boumber YA, Shu J, Qin T, Ahmed S, He R, Jelinek J, Issa JP: Chromatin
remodeling is required for gene reactivation after decitabine-mediated
DNA hypomethylation. Cancer Res 2010, 70:6968–6977.
87. Csoka AB, Szyf M: Epigenetic side-effects of common pharmaceuticals: a
potential new field in medicine and pharmacology. Med Hypotheses 2009,
73:770–780.
88. Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, Gray JW,
Leonhardt H, Jaenisch R: Induction of tumors in mice by genomic
hypomethylation. Science 2003, 300:489–492.
89. Holliday R, Pugh JE: DNA modification mechanisms and gene activity
during development. Science 1975, 187:226–232.
90. Bestor TH, Tycko B: Creation of genomic methylation patterns. Nat Genet
1996, 12:363–367.
91. Ehrlich M: DNA methylation in cancer: too much, but also too little.
Oncogene 2002, 21:5400–5413.
92. Vera E, Canela A, Fraga MF, Esteller M, Blasco MA: Epigenetic regulation of
telomeres in human cancer. Oncogene 2008, 27:6817–6833.
93. Feltus FA, Lee EK, Costello JF, Plass C, Vertino PM: DNA motifs associated
with aberrant CpG island methylation. Genomics 2006, 87:5728–5729.
94. Kang MI, Rhyu MG, Kim YH, Jung YC, Hong SJ, Cho CS, Kim HS: The length
of CpG islands is associated with the distribution of Alu and L1
retroelements. Genomics 2006, 87:580–590.
95. Deininger PL, Batzer MA: Alu repeats and human disease. Mol Genet Metab
1999, 67:183–193.
96. Hagemann S, Heil O, Lyko F, Brueckner B: 5-azacytidine and decitabine
induce gene-specific and non-random DNA demethylation in human
cancer cell lines. PLoS One 2011, 6:e17388.
97. Tárnok A: Cytomics for discovering drugs. Cytometry A 2010, 77:1–2.
98. Dostie J, Richmond TA, Arnaout RR, Selzer RA, Lee WL, Honan TA, Rubio ED,
Krumm A, Lamb J, Nusbaum C, Green RD, Dekker J: Chromosome
conformation capture carbon copy (5C): a massively parallel solution for
mapping interactions between genomic elements. Genome Res 2006,
16:1299–1309.
99. Lieberman-Aiden E, van Berkum NL, Williams L, Imakaev M, Ragoczy T,
Telling A, Amit I, Lajoie BR, Sabo PJ, Dorschner MO, Sandstrom R, Bernstein
B, Bender MA, Groudine M, Gnirke A, Stamatoyannopoulos J, Mirny LA,
Lander ES, Dekker J: Comprehensive mapping of long-range interactions
reveals folding principles of the human genome. Science 2009, 326:289–293.
100. Fullwood MJ, Fullwood MJ, Liu MH, Pan YF, Liu J, Xu H, Mohamed YB, Orlov
YL, Velkov S, Ho A, Mei PH, Chew EG, Huang PY, Welboren WJ, Han Y, Ooi
HS, Ariyaratne PN, Vega VB, Luo Y, Tan PY, Choy PY, Wansa KD, Zhao B, Lim
KS, Leow SC, Yow JS, Joseph R, Li H, Desai KV, Thomsen JS, et al: An
oestrogen-receptor-a-bound human chromatin interactome. Nature 2009,
462:58–64.
101. Goren A, Ozsolak F, Shoresh N, Ku M, Adli M, Hart C, Gymrek M, Zuk O,
Regev A, Milos PM, Bernstein BE: Chromatin profiling by directly
sequencing small quantities of immunoprecipitated DNA. Nat Methods
2010, 7:47–49.
doi:10.1186/2050-6511-14-11
Cite this article as: Gertych et al.: 3-D DNA methylation phenotypes
correlate with cytotoxicity levels in prostate and liver cancer cell models.
BMC Pharmacology and Toxicology 2013 14:11.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
